CoChat

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies

Open access
Strauss, Julius, Gatti-Mays, Margaret E, Cho, Byoung Chul, Hill, Andrew, Salas, Sébastien, McClay, Edward, Redman, Jason M, Sater, Houssein A, Donahue, Renee N, Jochems, Caroline, Lamping, Elizabeth, Burmeister, Andrea, Marté, Jennifer L, Cordes, Lisa M, Bilusic, Marijo, Karzai, Fatima, Ojalvo, Laureen S, Jehl, Genevieve, Rolfe, P Alexander, Hinrichs, Christian S, Madan, Ravi A, Schlom, Jeffrey, Gulley, James L · 2020 · Journal for ImmunoTherapy of Cancer
Cited by 153

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background: Bintrafusp alfa is a first-in-class bifunctional fusion protein composed of the extracellular domain of transforming growth factor (TGF)-βRII (a TGF-β ‘trap’) fused to a human IgG1 mAb blocking programmed cell death ligand 1. This is the largest analysis of patients with advanced, pretreated human papillomavirus (HPV)-associated malignancies treated with bintrafusp alfa. Methods: In these phase 1 (NCT02517398) and phase 2 trials (NCT03427411), 59 patients with advanced, pretreated, checkpoint inhibitor-naive HPV-associated cancers received bintrafusp alfa intravenously every 2 weeks until progressive disease, unacceptable toxicity, or withdrawal. Primary endpoint was best overall response per Response Evaluation Criteria in Solid Tumors (RECIST) V.1.1; other endpoints included safety. Results: As of April 17, 2019 (phase 1), and October 4, 2019 (phase 2), the confirmed objective response rate per RECIST V.1.1 in the checkpoint inhibitor-naive, full-analysis population was 30.5% (95% CI, 19.2% to 43.9%; five complete responses); eight patients had stable disease (disease control rate, 44.1% (95% CI, 31.2% to 57.6%)). In addition, three patients experienced a delayed partial response after initial disease progression, for a total clinical response rate of 35.6% (95% CI, 23.6% to 49.1%). An additional patient with vulvar cancer had an unconfirmed response. Forty-nine patients (83.1%) experienced treatment-related adverse events, which were grade 3/4 in 16 patients (27.1%). No treatment-related deaths occurred. Conclusion: Bintrafusp alfa showed clinical activity and manageable safety and is a promising treatment in HPV-associated cancers. These findings support further investigation of bintrafusp alfa in patients with advanced, pretreated HPV-associated cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-001395

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 153

Metadata

Authors
Strauss, J., Gatti-Mays, M. E., Cho, B. C., Hill, A., Salas, S., McClay, E., Redman, J. M., Sater, H. A., Donahue, R. N., Jochems, C., Lamping, E., Burmeister, A., Marté, J. L., Cordes, L. M., Bilusic, M., Karzai, F., Ojalvo, L. S., Jehl, G., Rolfe, P. A., Hinrichs, C. S., Madan, R. A., Schlom, J., & Gulley, J. L.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-12
Volume
8
Issue
2
Pages
e001395
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3110938402
Cited by
153
References
5
FWCI
6.82
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. https://app.cochat.ai/papers/10.1136/jitc-2020-001395
The paper
Strauss, J., Gatti-Mays, M. E., Cho, B. C., Hill, A., Salas, S., McClay, E., Redman, J. M., Sater, H. A., Donahue, R. N., Jochems, C., Lamping, E., Burmeister, A., Marté, J. L., Cordes, L. M., Bilusic, M., Karzai, F., Ojalvo, L. S., Jehl, G., Rolfe, P. A., . . . Gulley, J. L. (2020). Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2020-001395

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.